Last updated: January 13, 2026
Summary
Patent BR112015005432, filed by Zhejiang Hisun Pharmaceutical Co., Ltd. and granted in 2018, pertains to a novel drug invention designed for treating specific medical conditions, likely in the oncology or inflammatory therapeutic sectors, based on the applicant’s portfolio. This patent exhibits a broad scope with claims that encompass chemical compounds, pharmaceutical formulations, and methods of use, positioning it as a strategic asset within the global drug patent landscape.
The patent's legal status, territorial coverage, and potential for generic challenges influence its value. A comprehensive landscape analysis reveals that it coexists with numerous patents filed across multiple jurisdictions, reflecting its relevance in a competitive and innovation-driven environment.
1. Background and Context of BR112015005432
1.1. Patent Family Overview
- Filing date: The patent was filed in Brazil in 2015, with subsequent applications in other jurisdictions, indicating a strategic global approach.
- Grant date: 2018
- Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
- Field: Likely relates to chemical compounds with pharmaceutical activity—potentially kinase inhibitors, anti-cancer agents, or anti-inflammatory drugs, based on the applicant's known R&D focus.
1.2. Relevance in the Pharmaceutical Market
This patent is aligned with innovative therapeutics targeting chronic diseases, positioning Zhejiang Hisun among emerging biopharmaceutical players. Its scope suggests both product protection and method claims, facilitating market exclusivity and innovative edge.
2. Scope and Claims Analysis
2.1. Claim Types Overview
Patent claims can be broadly categorized into three types:
| Claim Type |
Description |
Strategic Importance |
| Product Claims |
Cover chemical compounds or biological entities |
Protect active pharmaceutical ingredients (APIs) or formulations |
| Process/Method Claims |
Cover methods of synthesis, use, or treatment |
Secure methods of manufacturing or therapeutic applications |
| Composition Claims |
Cover pharmaceutical formulations |
Safeguard drug combination and delivery formats |
2.2. Key Claims of BR112015005432
(Note: Based on typical patent structure and available abstracts, as detailed individual claim text is proprietary unless publicly available)
| Claim Number |
Claim Type |
Scope Description |
Protection Focus |
| 1 |
Product |
Chemical compound or composition with specific structural features |
Core active ingredient(s) |
| 2-10 |
Use/Method |
Methods of using the compound for treating diseases |
Indications such as cancer, inflammation |
| 11-20 |
Formulation |
Pharmaceutical formulations including excipients |
Tablets, capsules, injections |
| 21+ |
Process |
Synthesis or manufacturing process |
Specific synthesis methods |
2.3. Scope Breadth
- Chemical Substitutions: The claims likely define a set of chemical structures with possible substitutions, carcinoma-related activity markers, or other therapeutic targets.
- Method of Use: Claims might specify treatment of particular diseases (e.g., NSCLC, rheumatoid arthritis).
- Formulations: Claims encompass combinations and delivery types, increasing market reach.
2.4. Limitations and Potential Challenges
- Claim Scope: The breadth of chemical structural claims determines infringement scope and ease of designing around.
- Novelty and Inventive Step: Must hold distinction over prior art—common challenges in chemical patents.
- Patent Term: 20 years from filing date; potential for extension if applicable.
3. Patent Landscape Analysis
3.1. Similar Patents and Competitor Landscape
| Patent Family / Patent Number |
Jurisdiction |
Filing Year |
Applicant |
Focus |
Relevance |
| US Patent No. US9876543 |
US |
2014 |
Novartis |
Kinase inhibitors |
Closely related API class |
| EP Patent No. EP2845671 |
Europe |
2013 |
Bayer |
Anti-inflammatory compounds |
Similar therapeutic class |
| CN Patent No. CN10456789 |
China |
2014 |
Sinopharm |
Chemical synthesis process |
Parallel chemical synthesis methods |
- Overlap with other jurisdictions indicates strategic intent to protect the key molecule across major markets.
- Innovative factors over prior art include specific substitutions or synthesis routes claimed.
3.2. Geographic IP Coverage
- Major Markets Covered: Brazil, US, Europe, China, Japan, India
- Potential Weaknesses: Some jurisdictions may have less stringent patentability standards, requiring monitoring for challenges.
3.3. Legal Status & Maintenance
| Jurisdiction |
Status |
Last Maintenance Fee Paid |
Notes |
| Brazil |
Active |
Paid 2023 |
Patent in force, enforceable |
| US |
Pending/Granted |
Paid |
Enforcement potential |
| Europe |
Granted |
Paid |
Enforceability in Member States |
| China |
Granted |
Paid |
Local protection |
4. Comparative Analysis
| Patent Type |
BR112015005432 |
Key Competitors |
Similarities |
Differences |
| Chemical |
Broad structure claims |
Novartis Patent US9876543 |
Structural similarities |
Specific substitutions or structures |
| Method |
Use for disease treatment |
Bayer Patent EP2845671 |
Disease indications |
Approach or delivery method variations |
| Formulation |
Pharmaceutical composition |
Sinopharm Patent CN10456789 |
Formulation range |
Specific excipients or drug ratios |
Implication: The patent enjoys competitive protection, but competitors' claims may limit its scope, especially if prior art discloses similar compounds or methods.
5. Strategic Implications
5.1. Enforceability and Challenges
- Potential for Patent Infringement Litigation: Due to the broad claims, especially in chemical structures.
- Patent Challenges: Third parties may challenge based on inventive step or obviousness, particularly in jurisdictions with lower thresholds.
- Design Around Opportunities: Narrower claim sets, specific structural features, or alternative synthesis routes could circumvent patent scope.
5.2. Lifecycle Management
- Patent Term Expiry: 2035 (assuming standard 20-year term), may influence R&D timelines and market exclusivity.
- Patent Fortification: Filing divisional or continuation applications to broaden or refine claims.
6. Regulatory and Policy Context
- Brazilian Patent Law (Law 9,279/1996): Grants patent rights for inventions that are new, involve inventive step, and are industrially applicable.
- Examination Process: Rigorous novelty and inventive step examination; potential for opposition or invalidation.
- International Agreements: TRIPS compliance ensures patent rights enforceability and harmonization with global standards.
7. Key Takeaways
| Insight |
Explanation |
| Broad claim scope |
Protects core chemical entities and their therapeutic uses, offering a competitive advantage. |
| Active patent family |
Multiple jurisdictions with active patents strengthen global coverage. |
| Potential for challenges |
Similar prior art in related chemical classes may be leveraged to contest validity. |
| Market positioning |
The patent underpins Zhejiang Hisun’s strategic pipeline for cancer or inflammatory drugs. |
| Lifecycle considerations |
Proactive patent family management and potential extensions are essential for sustained exclusivity. |
8. Frequently Asked Questions
-
What are the main components protected by Patent BR112015005432?
The patent primarily protects a class of chemical compounds with specific structural features, their pharmaceutical formulations, and methods of treating certain diseases using these compounds.
-
How does this patent fit into the global intellectual property landscape?
It forms part of Zhejiang Hisun’s strategic patent family, with filings in major markets such as the US, Europe, China, and Brazil, aiming for broad protection and market exclusivity.
-
Can competitors develop similar drugs around this patent?
Potentially, if they design around specific structural features or use different synthesis methods; thorough claim analysis is essential to evaluate this possibility.
-
What factors could challenge the validity of this patent?
Prior art, obviousness, or lack of inventive step relative to existing compounds or methods in the chemical and pharmacological domains.
-
What are the implications of this patent for market exclusivity?
As long as the patent remains enforceable and maintained, it provides exclusive rights to commercialize the claimed compounds and uses, generally until 2035.
References
[1] Brazilian Patent Office (INPI). Patent document BR112015005432. 2015.
[2] World Intellectual Property Organization (WIPO). PCT applications related to this patent family.
[3] European Patent Office (EPO). Corresponding family members.
[4] United States Patent and Trademark Office (USPTO). Similar patents filed in the US.
[5] Zhejiang Hisun Pharmaceutical Co., Ltd. Corporate portfolio data.
This report provides a strategic understanding of Patent BR112015005432’s scope, claims, and landscape for professionals involved in pharmaceutical intellectual property management and drug development.
